GeneFerm Biotechnology Co Ltd (1796) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GeneFerm Biotechnology Co Ltd (1796) has a cash flow conversion efficiency ratio of 0.002x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$1.45 Million ≈ $45.65K USD) by net assets (NT$794.03 Million ≈ $25.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GeneFerm Biotechnology Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how GeneFerm Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 1796 current and long-term liabilities for a breakdown of total debt and financial obligations.
GeneFerm Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneFerm Biotechnology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
360 Capital Group
AU:TGP
|
0.011x |
|
Experience Co Ltd
AU:EXP
|
0.064x |
|
Polychem Indonesia Tbk
JK:ADMG
|
-0.015x |
|
Heungkuk Metaltech Co.Ltd
KQ:010240
|
0.017x |
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
-83.670x |
|
Orbit Garant Drilling Inc.
TO:OGD
|
0.064x |
|
180 Degree Capital Corp
NASDAQ:TURN
|
-0.083x |
|
Alchemy Investments Acquisition Corp 1 Class A Ordinary Shares
NASDAQ:ALCY
|
-0.962x |
Annual Cash Flow Conversion Efficiency for GeneFerm Biotechnology Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of GeneFerm Biotechnology Co Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see 1796 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$788.18 Million ≈ $24.83 Million |
NT$8.09 Million ≈ $254.88K |
0.010x | -95.18% |
| 2023-12-31 | NT$892.84 Million ≈ $28.13 Million |
NT$190.31 Million ≈ $6.00 Million |
0.213x | +44.64% |
| 2022-12-31 | NT$830.77 Million ≈ $26.17 Million |
NT$122.43 Million ≈ $3.86 Million |
0.147x | -1.82% |
| 2021-12-31 | NT$747.66 Million ≈ $23.56 Million |
NT$112.23 Million ≈ $3.54 Million |
0.150x | +5.41% |
| 2020-12-31 | NT$396.19 Million ≈ $12.48 Million |
NT$56.42 Million ≈ $1.78 Million |
0.142x | +825.46% |
| 2019-12-31 | NT$954.50 Million ≈ $30.07 Million |
NT$14.69 Million ≈ $462.72K |
0.015x | -84.79% |
| 2018-12-31 | NT$416.51 Million ≈ $13.12 Million |
NT$42.14 Million ≈ $1.33 Million |
0.101x | -47.83% |
| 2017-12-31 | NT$314.95 Million ≈ $9.92 Million |
NT$61.08 Million ≈ $1.92 Million |
0.194x | -- |
About GeneFerm Biotechnology Co Ltd
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health products in Taiwan and internationally. The company offers microbial fermentation products, including fungi, bacteria, lactic acid bacteria, yeast, algae, etc.; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reis… Read more